MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property

MOUNTAIN VIEW, Calif., Oct 21 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Thomas P. McCracken as Vice President, Intellectual Property. Mr. McCracken will lead the company's intellectual property program in support of the potential commercialization of the company's lead product candidate, LEVADEX™ orally inhaled migraine therapy, and other product opportunities.

Mr. McCracken has extensive legal experience within the healthcare industry. Most recently, Mr. McCracken was Vice President and Chief Patent Counsel at Durect Corporation, where he was responsible for management, development and creation of all intellectual property assets.  He was previously with PowderJect Pharmaceuticals, where he was responsible for managing IP assets and services across all research and development functions of the company, including vaccines, biopharmaceuticals and medical devices.   Prior to PowderJect, Mr. McCracken was in private patent law practice and specialized in the areas of pharmaceuticals, biotechnology, biomedical engineering and medical devices. His knowledge of the biotechnology field is further supplemented with several years of technical experience in research and development at privately held biopharmaceutical companies, including research activities at the Research Institute of Scripps Clinic.

"Tom joins the company at an ideal time, as his expertise in patent and trademark planning, patent claims structuring and technology licensing will benefit us as we prepare for the potential commercialization of LEVADEX and develop other potential pipeline products," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals.

Mr. McCracken holds a Bachelor's degree in Microbiology from the University of California, San Diego and a Juris Doctor degree from Santa Clara University School of Law.  He is registered to practice with the U.S. Patent and Trademark Office and is a member of the State Bar of California.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating the conduct and completion of clinical trials, and relating to the preparation and filing of a New Drug Application and the regulatory process to have the Company's LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, available at http://edgar.sec.gov.

SOURCE MAP Pharmaceuticals, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED